Mereo BioPharma Group Securities Fraud Class Action

Mereo BioPharma Group Securities Fraud Investigation

Contact UsFree Case Evaluation

"*" indicates required fields

First Name*

Last Name*

Email Address*

Phone Number*

Practice Area

City*

State or Province*

Please describe your potential case or matter.**

By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.

Practice Area: Securities Fraud & Investor Protection

Case Status: Pending

Ticker Symbol: NASDAQ: MREO

Investigation Deadline: April 6, 2026

A class action lawsuit has been filed against Mereo BioPharma Group plc (NASDAQ: MREO) on behalf of investors who purchased American Depositary Shares (“ADS”) issued by Mereo during the period from June 5, 2023 through December 26, 2025 (the “Class Period”).

Investor Deadline: Investors who purchased Mereo securities during the Class Period may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class.

If you are a Mereo investor and would like to learn more about this action, please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About the Mereo BioPharma Group Class Action

Mereo is a biopharmaceutical company focused on developing therapies for rare and serious diseases. The Company is headquartered in London, UK.

According to the lawsuit, throughout the Class Period, defendants issued overwhelmingly positive statements to investors concerning the ORBIT and COSMIC Phase 3 programs, clinical trials to test setrusumab as a treatment for Osteogenesis Imperfecta.

When, on December 29, 2025, Mereo disclosed that neither study achieved its primary endpoint of reducing the annualized clinical fracture rate, the price of its ADS dropped more than 87%, from a closing price of $2.31 per share on December 26, 2025 to a close of $0.29 per share on December 29, 2025.